ASM Global’s Rapidly Expanding Convention Division Unveils Exhibition World Bahrain, Middle East’s Largest Exhibition Centre
ASM Global, the world’s leading venue management company and producer of live experiences, has made history with the spectacular firework-laden inauguration ceremony of the 950,000-square-foot Exhibition World Bahrain—the largest exhibition centre in the Middle East.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005879/en/
Image courtesy of ASM Global
The Kingdom’s Exhibition World is one of the most contemporary such venues in the world. Its launch is a milestone in the Kingdom’s economic development and is expected to play a key role in advancing the economic competitiveness and positioning of Bahrain as a major global destination for regional and international conventions.
The venue joins ASM Global’s portfolio of more than 350 venues around the world and kicks off the company’s post-pandemic convention growth initiative.
ASM Global’s President and CEO Ron Bension said, “This moment is the culmination of our plan developed during the pandemic leveraging our belief that this part of the world would be the quickest to not only return to normal but move quickly to dramatically increase its convention and exhibition market share.
“We’re also looking forward to leveraging the widest network in the world within the MICE industry to create unique experiences built on years of expertise.”
The opening extravaganza was attended on behalf of His Majesty King Hamad bin Isa Al Khalifa, by His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister of Bahrain.
HRH Prince Salman bin Hamad highlighted the importance of competitiveness as a fundamental element of the kingdom’s economy, which has bolstered investments, promoted economic progress and created quality opportunities for citizens. He also noted that tourism remains a leading economic sector, adding that the sector's growth has been a key driver of the kingdom’s comprehensive development, led by His Majesty the King.
During the ceremony, Bahrain Tourism Minister H.E. Fatima Al Sairafi noted the kingdom’s longstanding history in being a destination linking the east and west for trade, which has furthered its position as a global tourist destination. She added that the inauguration of the venue reflects the kingdom’s commitment to expanding cross-sector development in line with Bahrain's sustainable development goals.
Exhibition World Bahrain is unique for its adaptable and flexible design, featuring 10 halls with a combined total of 95,000 sqm. The spectacular Grand Hall has a capacity of 4,000 seated guests and is supported by 94 meeting rooms as well as 25 F&B and retail outlets throughout the exhibition concourse. The centre’s spacious design enables it to host a number of events simultaneously, making it an attractive location for local, regional and international exhibitions, conventions, galas, weddings, concerts, sports, and live entertainment events.
Exhibition World Bahrain is owned by the Bahrain Tourism and Exhibitions Authority (BTEA), which plans to utilize ASM Global’s wider network within the MICE industry to create unique experiences built on years of expertise.
ASM Global APAC and Gulf Region Chairman and Chief Executive Harvey Lister AM congratulated BTEA on the inauguration of Exhibition World Bahrain, one of the Middle East’s largest exhibition and convention centres.
“ASM Global is proud to be working in partnership with BTEA helping to ensure Bahrain will be at the forefront of attracting tourism investment, international conventions and exhibitions and world-class live events to the Gulf region,” Lister said. “This iconic landmark venue will further position Bahrain as an international destination, helping to drive diversification of growth, benefiting the local economy and further enhancing the kingdom’s global standing.”
Exhibition World Bahrain General Manager Dr Debbie Kristiansen said she was extremely proud of her dedicated and committed team and their passion and determination to “give back” to the beautiful country of Bahrain, helping to create long-term legacies for the future. Dr Kristiansen highlighted the importance of mentoring and building the talent and skillset of young Bahrainis describing it as a “privilege.”
Following the grand opening, Exhibition World Bahrain immediately opened to the public with three concurrent events expected to see well over 100,000 visitors over the span of five days: Jewellery Arabia, the premier jewellery and watch show celebrating its 30th edition; Scent Arabia’s first-ever exhibition; and Cityscape, the region’s largest real estate summit and exhibition.
ASM Global’s network hosts 20,000 events and welcomes 165 million guests every year. Other flagship exhibition and convention centres in its portfolio include McCormick Place in Chicago; Moscone Center in San Francisco; ICC Sydney; Shenzhen World in China; and P&J Live in Aberdeen, U.K.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centres, and performing arts venues. Follow us on Facebook, Instagram, Twitter and LinkedIn. asmglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005879/en/
Contact information
PRESS CONTACT:
Jim Yeager
jim@breakwhitelight.com (for ASM Global)
Mobile: 818-264-6812
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom